News & Events

Disc Medicine to Present at the Virtual 62nd American Society of Hematology Annual Meeting

CAMBRIDGE, Mass. (December 2, 2020) – Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapeutic candidates for serious and debilitating hematologic diseases, today announced that preclinical data from two pipeline programs that modulate the hepcidin

More News

Disc Medicine Reports First Quarter 2023 Financial Results and Provides Business Update

Two ongoing Phase 2 studies of bitopertin in EPP; initial safety and efficacy data from open-label BEACON trial to be presented at...


read more

Disc Medicine Announces Presentation of Initial Data from Phase 2 BEACON Trial in Patients with Erythropoietic Protoporphyria (EPP) at European Hematology Association (EHA) 2023 Congress

WATERTOWN, Mass., May 11, 2023 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and...


read more

Disc Medicine to Participate in H.C. Wainwright BioConnect Investor Conference

WATERTOWN, Mass., April 21, 2023 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and...


read more